Cargando…

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer

This study was performed to investigate the prevalence, clinical characteristics, and treatment response according to BRCA1 and BRCA2 (BRCA) mutations in Korean patients with epithelial ovarian cancer (EOC). Two‐hundred and ninety‐eight Korean women diagnosed with high‐grade serous and/or endometrio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paik, E Sun, Heo, Eun Jin, Choi, Chel Hun, Kim, Jae‐Hoon, Kim, Jae‐Weon, Kim, Yong‐Man, Park, Sang‐Yoon, Lee, Jeong‐Won, Kim, Jong‐Won, Kim, Byoung‐Gie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645710/ https://www.ncbi.nlm.nih.gov/pubmed/34657357 http://dx.doi.org/10.1111/cas.15166

Ejemplares similares

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
por: Seo, Jun Hyeong, et al.
Publicado: (2019)

Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko‐EVE)
por: Sung, Soseul, et al.
Publicado: (2023)

Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
por: Bang, Yoon Ju, et al.
Publicado: (2022)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification
por: Paik, E Sun, et al.
Publicado: (2015)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods
por: Paik, E Sun, et al.
Publicado: (2019)

Primary ovarian choriocarcinoma mimicking ectopic pregnancy
por: Heo, Eun Jin, et al.
Publicado: (2014)

Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
por: Paik, E Sun, et al.
Publicado: (2018)

Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
por: Kim, Jihye, et al.
Publicado: (2018)

Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases
por: Paik, E Sun, et al.
Publicado: (2019)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2
por: Eoh, Kyung Jin, et al.
Publicado: (2018)

Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
por: Lee, Yoo-Young, et al.
Publicado: (2015)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients
por: Ahn, Sei Hyun, et al.
Publicado: (2004)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
por: Kim, Se Ik, et al.
Publicado: (2020)

The anti-cancer effects of itraconazole in epithelial ovarian cancer
por: Choi, Chel Hun, et al.
Publicado: (2017)

Performance evaluation of an amplicon‐based next‐generation sequencing panel for BRCA1 and BRCA2 variant detection
por: Park, Kuenyoul, et al.
Publicado: (2020)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
por: Lee, Young-Jae, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2017)

Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer
por: Park, Jin-Young, et al.
Publicado: (2016)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
por: Lee, Maria, et al.
Publicado: (2019)

Histologic distribution of borderline ovarian tumors worldwide: a systematic review
por: Song, Taejong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_40fnma5d3trvhu0ducr4fhqal4